These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12945473)

  • 21. Lipid-lowering agents and hepatotoxicity.
    Demyen M; Alkhalloufi K; Pyrsopoulos NT
    Clin Liver Dis; 2013 Nov; 17(4):699-714, x. PubMed ID: 24099026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
    Samson RH; Nair DG
    Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations of the second Indo-U.S. health summit on prevention and control of cardiovascular disease among Asian Indians.
    Enas EA; Singh V; Munjal YP; Gupta R; Patel KC; Bhandari S; Agarwal AK; Joshi SR; Anoop M; Prabhakaran D; Shah B; Reddy S; Sharma B; Trehan N; Yavagal ST; Kasliwal RR;
    Indian Heart J; 2009; 61(3):265-74. PubMed ID: 20503833
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent trials of lipid lowering.
    Ray KK; Cannon CP; Braunwald E
    Int J Clin Pract; 2007 Jul; 61(7):1145-59. PubMed ID: 17577297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid lowering strategies.
    Morrell J
    Indian Heart J; 1999; 51(5):489-93. PubMed ID: 10721637
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.
    Ramsay LE; Haq IU; Jackson PR; Yeo WW; Pickin DM; Payne JN
    Lancet; 1996 Aug; 348(9024):387-8. PubMed ID: 8709740
    [No Abstract]   [Full Text] [Related]  

  • 27. All at sea: new lipid-lowering drug trials continue to disappoint.
    Wierzbicki AS
    Int J Clin Pract; 2013 Jul; 67(7):595-8. PubMed ID: 23758438
    [No Abstract]   [Full Text] [Related]  

  • 28. [Nutrition in patients treated with antilipemic agents. Survey of 337 patients].
    Bernard MC; Renucci JF; Tosello N; Gouvernet J; Vague P
    Presse Med; 1997 Apr; 26(13):598-602. PubMed ID: 9180868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reflections on cardiovascular risk estimates in primary prevention.
    Lou Arnal S; Molinero AV
    Rev Esp Cardiol; 2009 Feb; 62(2):228-9; author reply 229-30. PubMed ID: 19232201
    [No Abstract]   [Full Text] [Related]  

  • 30. Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
    Schooling CM; Au Yeung SL; Leung GM
    Eur J Clin Invest; 2014 Nov; 44(11):1135-40. PubMed ID: 25252212
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
    Tomasik T; Windak A; Seifert B; Kersnik J; Kijowska V; Dubas K
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):234-42. PubMed ID: 23277158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiovascular diseases. Diet and prevention].
    Revol E
    Soins; 1996; (602-603):11-4. PubMed ID: 8715754
    [No Abstract]   [Full Text] [Related]  

  • 34. [Update of lipid lowering therapy].
    Riesen WF; Mordasini RC
    Praxis (Bern 1994); 2008 Nov; 97(22):1179-84. PubMed ID: 18979436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary prevention in stroke. When we might extrapolate.
    Lewis LS
    BMJ; 2009 May; 338():b2097. PubMed ID: 19474012
    [No Abstract]   [Full Text] [Related]  

  • 37. [New European guidelines for the management of dyslipidaemia in cardiovascular prevention].
    Descamps OS; De Backer G; Annemans L; Muls E; Scheen AJ; ;
    Rev Med Liege; 2012 Mar; 67(3):118-27. PubMed ID: 22611827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An educational and behavioral approach for the primary prevention of premature cardiovascular disease.
    Allred CA; Smith RP; Dudenas VC; Ayers CR
    J Am Diet Assoc; 1984 Sep; 84(9):1042-3. PubMed ID: 6470376
    [No Abstract]   [Full Text] [Related]  

  • 40. Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?
    Bansal M; Agarwala R
    Indian Heart J; 2018; 70(3):331-334. PubMed ID: 29961445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.